ArticleThe British journal of ophthalmology2015
UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12.
Article in The British journal of ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review.Eye (London, England) · 2023Pooled it
- Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA.The British journal of ophthalmology · 2020Trial
- Early detection of neovascular age-related macular degeneration in the second eye reduces intravitreal treatment burden: FASBAT report 2.Eye (London, England) · 2026Observational
- Home Monitoring for the Management of Age-Related Macular Degeneration: A Review of the Development and Implementation of Digital Health Solutions over a 25-Year Scientific Journey.Medicina (Kaunas, Lithuania) · 2025Review
- Predicting long-term functional anti-VEGF treatment outcomes in neovascular AMD in a real-world setting.PloS one · 2024Article
- Associations with baseline visual acuity in 12,414 eyes starting treatment for neovascular AMD.Eye (London, England) · 2023Article
- What about the fellow eye in treatment of neovascular age-related macular degeneration? Analysis of data from the Swedish macula register.Acta ophthalmologica · 2022Observational
- Evolving Treatment Patterns and Outcomes of Neovascular Age-Related Macular Degeneration Over a Decade.Ophthalmology. Retina · 2021Article
- Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration.Journal of clinical medicine · 2021Article
- Age-Related Macular Degeneration: Epidemiology and Clinical Aspects.Advances in experimental medicine and biology · 2021Article
- Article
- Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration.Eye (London, England) · 2020Article
- CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: An Expert Panel Consensus.Retina (Philadelphia, Pa.) · 2020Review
- Providing a Safe and Effective Intravitreal Treatment Service: Strategies for Service Delivery.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Trends in Real-World Neovascular AMD Treatment Outcomes in the UK.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- Observational
- Complement factor B knockdown by short hairpin RNA inhibits laser-induced choroidal neovascularization in rats.International journal of ophthalmology · 2020Article
- Presymptomatic Retinal Sensitivity Changes in Intermediate Age-Related Macular Degeneration Associated With New Retinal Fluid.Translational vision science & technology · 2019Article
- [Analysis of real-life data on treatment quality in patients with exudative age-related macular degeneration (AMD) and vein occlusion at a German university eye hospital].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2019Article
- Imaging Characteristics of Choroidal Neovascular Lesions in the AREDS2-HOME Study: Report Number 4.Ophthalmology. Retina · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 18 institutions in 4 countries.
Funding
Abstract
BACKGROUND/
aimsTo study the effectiveness and clinical relevance of eyes treated with good (better than 6/12 or >70 Early Treatment Diabetic Retinopathy Study letters) visual acuity (VA) when initiating treatment with ranibizumab for neovascular age-related macular degeneration (nAMD) in the UK National Health Service. Currently eyes with VA better than (>) 6/12 are not routinely funded for therapy.
methodsMulticentre national nAMD database study on patients treated 3-5 years prior to the analysis. Anonymised structured data were collected from 14 centres. The primary outcome was the mean VA at year 1, 2 and 3. Secondary measures included the number of clinic visits and injections.
resultsThe study included 12 951 treatment-naive eyes of 11 135 patients receiving 92 976 ranibizumab treatment episodes. A total of 754 patients had baseline VA better than 6/12 and at least 1-year of follow up. Mean VA of first treated eyes with baseline VA>6/12 at year 1, 2, 3 were 6/10, 6/12, 6/15, respectively and those with baseline VA 6/12 to >6/24 were 6/15, 6/17, 6/20, respectively (p values <0.001 for comparing differences between 6/12 and 6/12-6/24 groups). For the second eyes with baseline VA>6/12, mean VA at year 1, 2, 3 were 6/9, 6/9, 6/10 and those with baseline VA 6/12 to >6/24 were 6/15, 6/15, 6/27, respectively (p values <0.001-0.005). There was no significant difference in the average number of clinic visits or injections between those with VA better and worse than 6/12.
conclusionsAll eyes with baseline VA>6/12 maintained better mean VA than the eyes with baseline VA 6/12 to >6/24 at all time points for at least 2 years. The significantly better visual outcome in patients who were treated with good baseline VA has implications on future policy regarding the treatment criteria for nAMD patients' funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.